Skip to main content

Published locations for Ibrutinib offers better efficacy and tolerability over idelalisib+rituximab in relapsed/refractory CLL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ibrutinib offers better efficacy and tolerability over idelalisib+rituximab in relapsed/refractory CLL

User login

  • Reset your password
  • /content/ibrutinib-offers-better-efficacy-and-tolerability-over-idelalisibrituximab-relapsed
  • /hematology-oncology/article/262413/b-cell-lymphoma/ibrutinib-offers-better-efficacy-and-tolerability
  • /b-cell-lymphoma-icymi/article/262413/b-cell-lymphoma/ibrutinib-offers-better-efficacy-and